The Greater Cannabis Company, Inc. (GCAN)
| Previous Close | 0.0006 |
| Open | 0.0006 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0006 - 0.0008 |
| 52 Week Range | 0.0003 - 0.0015 |
| Volume | |
| Avg. Volume | 3,545,385 |
| Market Cap | 563,246 |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireGCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company had previously announced the preclinical study as part of its license and research agreement with Shaare Zedek Scientific related
- GlobeNewswire
GCANRx Featured in American Journal of Endocannabinoid Medicine
BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that the Company and its scientific advisor, Dr. Adi Aran, has been featured in the American Journal of Endocannabinoid Medicine (AJEM). The feature, which can be found here, discusses the autism-cannabis connection and the mounting evidence of the therapeutic
- GlobeNewswire
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that it has been granted final approval for its double blind, placebo controlled Phase II Clinical Trial for the treatment of Autism Spectrum Disorder (ASD) from the Israel Ministry of Health. The Company previously announced that it is planning to conduct a Pha
